ERBB2 and breast cancer: In detail, among patients with HER2-0 phenotype on baseline biopsy, 33.8% (n = 26) experienced a conversion to HER2-low-positive phenotype, while 37.7% (n = 43) of HER2-low-positive breast cancer patients showed a conversion in the opposite direction.